Travere Therapeutics Stock Rises 33% to $40.83
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 14 2026
0mins
Should l Buy TVTX?
Travere Therapeutics is up 33.0%, or $10.13 to $40.83.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TVTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TVTX
Wall Street analysts forecast TVTX stock price to rise
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 40.810
Low
31.00
Averages
42.89
High
49.00
Current: 40.810
Low
31.00
Averages
42.89
High
49.00
About TVTX
Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. FILSPARI is an oral, once-daily, non-immunosuppressive medication that directly targets glomerular injury in the kidney. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC, are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Travere Therapeutics Director Sells Shares Amid FDA Approval
- Transaction Overview: Gary A. Lyons, a director at Travere Therapeutics, sold 8,000 shares of common stock for approximately $329,000 on April 14, 2026, resulting in a 12.21% reduction in his direct holdings to 57,500 shares, valued at about $2.42 million post-transaction.
- Options Exercise Context: The sale was facilitated by exercising 8,000 stock options, all of which were sold immediately in the open market, indicating a relatively stable strategy in light of his current holdings base.
- Company Financial Performance: Travere Therapeutics reported $322 million in net product sales for 2025, a 144% year-over-year increase, and achieved $81.1 million in non-GAAP net income, a significant turnaround from a $241 million non-GAAP net loss in 2024.
- Market Potential Analysis: The recent FDA approval of FILSPARI for focal segmental glomerulosclerosis opens a new market estimated to serve over 30,000 patients, alongside the existing IgAN patient base, significantly enhancing the company's growth prospects.
See More
Travere Therapeutics Secures FDA Approval for Filspari
- Stock Surge: Travere Therapeutics' share price surged by 40.78% week-on-week as investors increased their positions following FDA approval for its kidney disease treatment, Filspari, indicating strong market confidence in the company's growth prospects.
- FDA Approval Details: Filspari has been approved by the FDA for treating patients aged 8 and above with focal segmental glomerulosclerosis (FSGS), making it the only FDA-approved medication for this condition, further solidifying the company's leadership in rare kidney diseases.
- Clinical Trial Results: In a successful phase 3 study, Filspari achieved a 46% reduction in proteinuria at week 108, compared to 30% for the maximum labeled dose of irbesartan, demonstrating significant therapeutic advantages, particularly in patients without nephrotic syndrome.
- Market Potential Expansion: The approval of Filspari expands its potential reach to over 100,000 patients in the US suffering from FSGS and IgAN, enhancing Travere Therapeutics' competitive position in the rare kidney disease treatment market.
See More
US Stocks Surge as Oil Prices Plunge Amid Ceasefire Talks
- Market Rally: The S&P 500 rose by 1.18%, reaching a two-month high, while the Nasdaq 100 increased by 1.81%, reflecting strong investor optimism ahead of the earnings season, particularly as major banks prepare to report.
- Oil Price Plunge: WTI crude oil prices fell over 7% due to potential US-Iran ceasefire extensions, which will lower jet fuel costs for airlines, thereby boosting profitability and further supporting stock market gains.
- Inflation Data Impact: The March PPI report showed a 4.0% year-over-year increase, below the expected 4.6%, indicating easing inflation pressures that could influence the Fed's rate hike decisions, leading to more cautious market expectations regarding future monetary policy.
- Airline Stocks Surge: American Airlines Group saw its stock rise over 8% as a result of falling oil prices, demonstrating market confidence in the airline industry's recovery and reflecting investor optimism about the profitability potential from lower fuel costs.
See More
Travere Therapeutics Grants Equity Inducements to New Employees
- Equity Incentive Program: On April 10, 2026, Travere Therapeutics granted a total of 17,420 restricted stock units (RSUs) to five new employees, aimed at attracting talent and enhancing employee loyalty.
- Grant Conditions: These RSUs were awarded under Travere's 2018 Equity Incentive Plan, although granted as inducements, they comply with Nasdaq Listing Rule 5635(c)(4), reflecting the company's commitment to regulatory compliance.
- Vesting Arrangement: The RSUs vest over four years with 25% vesting annually, which not only incentivizes long-term employee retention but also ensures ongoing contributions during their service with the company.
- Company Mission: Travere Therapeutics is dedicated to providing treatment options for rare disease patients, emphasizing collaboration with the rare disease community to develop and deliver life-changing therapies, showcasing the company's deep commitment to patient care.
See More
US Stocks Rally as Oil Prices Plunge
- Strong Market Performance: The S&P 500 rose by 0.77%, the Dow Jones by 0.59%, and the Nasdaq 100 by 0.98%, reflecting optimism about economic recovery, particularly with the potential extension of the US-Iran ceasefire.
- Significant Oil Price Drop: WTI crude oil prices fell over 5% due to optimistic expectations surrounding US-Iran negotiations, which not only alleviates inflationary pressures but may also support the stock market, indicating confidence in future economic growth.
- Inflation Data Impact: The US March PPI rose 4.0% year-over-year, below the expected 4.6%, suggesting that rising fuel prices are slowly filtering into inflation statistics, potentially prompting the Fed to adopt a more dovish stance in upcoming policy meetings.
- Earnings Season Approaches: Q1 earnings for the S&P 500 are projected to increase by 12% year-over-year, although the growth is only 3% when excluding the tech sector, indicating a mix of expectations and caution among investors that could influence decision-making.
See More
US Stocks Rise on Hopes of Iran Ceasefire Negotiations
- Market Rebound: The S&P 500 index rose by 0.39%, the Dow Jones Industrial Average increased by 0.13%, and the Nasdaq 100 index climbed by 0.76%, reflecting investor optimism regarding potential extensions of the ceasefire between the US and Iran, thereby boosting market confidence.
- Oil Price Decline: WTI crude oil prices fell by over 3% on hopes of US-Iran negotiations, which could alleviate global oil and gas shortages, impacting the earnings outlook for related energy companies.
- Inflation Data Impact: The US March PPI rose by 4.0% year-on-year, below the market expectation of 4.6%, indicating that the impact of high fuel prices on inflation is slowing, which may influence the Federal Reserve's monetary policy decisions.
- Earnings Season Approaches: Q1 earnings for the S&P 500 are projected to increase by 12% year-on-year, but excluding the technology sector, growth is only expected to be around 3%, indicating signs of economic slowdown that could affect investor confidence in the market.
See More
Travere Therapeutics Director Sells Shares Amid FDA Approval
- Transaction Overview: Gary A. Lyons, a director at Travere Therapeutics, sold 8,000 shares of common stock for approximately $329,000 on April 14, 2026, resulting in a 12.21% reduction in his direct holdings to 57,500 shares, valued at about $2.42 million post-transaction.
- Options Exercise Context: The sale was facilitated by exercising 8,000 stock options, all of which were sold immediately in the open market, indicating a relatively stable strategy in light of his current holdings base.
- Company Financial Performance: Travere Therapeutics reported $322 million in net product sales for 2025, a 144% year-over-year increase, and achieved $81.1 million in non-GAAP net income, a significant turnaround from a $241 million non-GAAP net loss in 2024.
- Market Potential Analysis: The recent FDA approval of FILSPARI for focal segmental glomerulosclerosis opens a new market estimated to serve over 30,000 patients, alongside the existing IgAN patient base, significantly enhancing the company's growth prospects.
See More
Travere Therapeutics Secures FDA Approval for Filspari
- Stock Surge: Travere Therapeutics' share price surged by 40.78% week-on-week as investors increased their positions following FDA approval for its kidney disease treatment, Filspari, indicating strong market confidence in the company's growth prospects.
- FDA Approval Details: Filspari has been approved by the FDA for treating patients aged 8 and above with focal segmental glomerulosclerosis (FSGS), making it the only FDA-approved medication for this condition, further solidifying the company's leadership in rare kidney diseases.
- Clinical Trial Results: In a successful phase 3 study, Filspari achieved a 46% reduction in proteinuria at week 108, compared to 30% for the maximum labeled dose of irbesartan, demonstrating significant therapeutic advantages, particularly in patients without nephrotic syndrome.
- Market Potential Expansion: The approval of Filspari expands its potential reach to over 100,000 patients in the US suffering from FSGS and IgAN, enhancing Travere Therapeutics' competitive position in the rare kidney disease treatment market.
See More
US Stocks Surge as Oil Prices Plunge Amid Ceasefire Talks
- Market Rally: The S&P 500 rose by 1.18%, reaching a two-month high, while the Nasdaq 100 increased by 1.81%, reflecting strong investor optimism ahead of the earnings season, particularly as major banks prepare to report.
- Oil Price Plunge: WTI crude oil prices fell over 7% due to potential US-Iran ceasefire extensions, which will lower jet fuel costs for airlines, thereby boosting profitability and further supporting stock market gains.
- Inflation Data Impact: The March PPI report showed a 4.0% year-over-year increase, below the expected 4.6%, indicating easing inflation pressures that could influence the Fed's rate hike decisions, leading to more cautious market expectations regarding future monetary policy.
- Airline Stocks Surge: American Airlines Group saw its stock rise over 8% as a result of falling oil prices, demonstrating market confidence in the airline industry's recovery and reflecting investor optimism about the profitability potential from lower fuel costs.
See More
Travere Therapeutics Grants Equity Inducements to New Employees
- Equity Incentive Program: On April 10, 2026, Travere Therapeutics granted a total of 17,420 restricted stock units (RSUs) to five new employees, aimed at attracting talent and enhancing employee loyalty.
- Grant Conditions: These RSUs were awarded under Travere's 2018 Equity Incentive Plan, although granted as inducements, they comply with Nasdaq Listing Rule 5635(c)(4), reflecting the company's commitment to regulatory compliance.
- Vesting Arrangement: The RSUs vest over four years with 25% vesting annually, which not only incentivizes long-term employee retention but also ensures ongoing contributions during their service with the company.
- Company Mission: Travere Therapeutics is dedicated to providing treatment options for rare disease patients, emphasizing collaboration with the rare disease community to develop and deliver life-changing therapies, showcasing the company's deep commitment to patient care.
See More
US Stocks Rally as Oil Prices Plunge
- Strong Market Performance: The S&P 500 rose by 0.77%, the Dow Jones by 0.59%, and the Nasdaq 100 by 0.98%, reflecting optimism about economic recovery, particularly with the potential extension of the US-Iran ceasefire.
- Significant Oil Price Drop: WTI crude oil prices fell over 5% due to optimistic expectations surrounding US-Iran negotiations, which not only alleviates inflationary pressures but may also support the stock market, indicating confidence in future economic growth.
- Inflation Data Impact: The US March PPI rose 4.0% year-over-year, below the expected 4.6%, suggesting that rising fuel prices are slowly filtering into inflation statistics, potentially prompting the Fed to adopt a more dovish stance in upcoming policy meetings.
- Earnings Season Approaches: Q1 earnings for the S&P 500 are projected to increase by 12% year-over-year, although the growth is only 3% when excluding the tech sector, indicating a mix of expectations and caution among investors that could influence decision-making.
See More
US Stocks Rise on Hopes of Iran Ceasefire Negotiations
- Market Rebound: The S&P 500 index rose by 0.39%, the Dow Jones Industrial Average increased by 0.13%, and the Nasdaq 100 index climbed by 0.76%, reflecting investor optimism regarding potential extensions of the ceasefire between the US and Iran, thereby boosting market confidence.
- Oil Price Decline: WTI crude oil prices fell by over 3% on hopes of US-Iran negotiations, which could alleviate global oil and gas shortages, impacting the earnings outlook for related energy companies.
- Inflation Data Impact: The US March PPI rose by 4.0% year-on-year, below the market expectation of 4.6%, indicating that the impact of high fuel prices on inflation is slowing, which may influence the Federal Reserve's monetary policy decisions.
- Earnings Season Approaches: Q1 earnings for the S&P 500 are projected to increase by 12% year-on-year, but excluding the technology sector, growth is only expected to be around 3%, indicating signs of economic slowdown that could affect investor confidence in the market.
See More
